Hilary Thomas

1.8k total citations · 1 hit paper
26 papers, 1.4k citations indexed

About

Hilary Thomas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hilary Thomas has authored 26 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Hilary Thomas's work include HER2/EGFR in Cancer Research (7 papers), Colorectal Cancer Treatments and Studies (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Hilary Thomas is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Colorectal Cancer Treatments and Studies (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Hilary Thomas collaborates with scholars based in United Kingdom, United States and Sweden. Hilary Thomas's co-authors include Helen M. Coley, Fatima H. Labeed, Michael Hughes, Helmout Modjtahedi, Margaret Green, C Shotton, Matthew Cunningham, Frances R. Balkwill, C. Topham and Sharadah Essapen and has published in prestigious journals such as Journal of Clinical Oncology, Contemporary Sociology A Journal of Reviews and Cancer Research.

In The Last Decade

Hilary Thomas

26 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

2003 769 citations Hilary Thomas, Helen M. Coley Cancer Control profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hilary Thomas United Kingdom	17	808	606	220	144	132	26	1.4k
Jean‐Pierre Gillet United States	16	876 1.1×	1.0k 1.7×	110 0.5×	145 1.0×	110 0.8×	29	1.7k
Kristen M. Pluchino United States	10	1.1k 1.4×	1.0k 1.7×	180 0.8×	196 1.4×	163 1.2×	14	2.0k
Dhaval K. Shah United States	31	1.1k 1.4×	1.1k 1.8×	268 1.2×	157 1.1×	57 0.4×	109	2.7k
Yi‐Jun Wang United States	29	1.6k 2.0×	982 1.6×	122 0.6×	114 0.8×	128 1.0×	75	2.5k
Maria Palmisano United States	23	385 0.5×	503 0.8×	130 0.6×	148 1.0×	58 0.4×	85	1.5k
Michelle J. Henderson Australia	21	1.1k 1.4×	1.6k 2.6×	154 0.7×	183 1.3×	136 1.0×	40	2.5k
Ding‐Wu Shen United States	18	999 1.2×	1.1k 1.9×	187 0.8×	207 1.4×	41 0.3×	24	2.1k
Eugene Mechetner United States	19	1.0k 1.3×	706 1.2×	45 0.2×	115 0.8×	227 1.7×	39	1.8k
Hiroshi Kuga Japan	14	676 0.8×	840 1.4×	69 0.3×	108 0.8×	71 0.5×	28	1.3k
Qiu‐Xu Teng United States	25	964 1.2×	932 1.5×	73 0.3×	82 0.6×	164 1.2×	50	1.6k

Countries citing papers authored by Hilary Thomas

Since Specialization

Citations

This map shows the geographic impact of Hilary Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilary Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilary Thomas more than expected).

Fields of papers citing papers by Hilary Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilary Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilary Thomas. The network helps show where Hilary Thomas may publish in the future.

Co-authorship network of co-authors of Hilary Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Hilary Thomas. A scholar is included among the top collaborators of Hilary Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilary Thomas. Hilary Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ricketts, William, et al.. (2024). AI-based approach to enable proactive identification of early lung cancer: A retrospective population health study and economic model.. Journal of Clinical Oncology. 42(16_suppl). 10536–10536. 1 indexed citations

Dueland, Svein, Steinar Aamdal, Michael Lind, et al.. (2008). Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study. Acta Oncologica. 48(1). 137–145. 27 indexed citations

Coley, Helen M., C Shotton, & Hilary Thomas. (2007). Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.. PubMed. 27(1A). 273–8. 11 indexed citations

Cunningham, Matthew, Hilary Thomas, Zhen Fan, & Helmout Modjtahedi. (2006). Responses of Human Colorectal Tumor Cells to Treatment with the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib. Cancer Research. 66(15). 7708–7715. 35 indexed citations

Thomas, Hilary. (2006). On patient stories.. PubMed. 116(6020). 23–23. 1 indexed citations

Cunningham, Matthew, Sharadah Essapen, Hilary Thomas, et al.. (2006). Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. International Journal of Oncology. 28(2). 329–35. 36 indexed citations

Mistry, Prakash, et al.. (2006). Mode of action of the novel phenazine anticancer agents XR11576 and XR5944. Anti-Cancer Drugs. 18(2). 139–148. 17 indexed citations

Coley, Helen M., et al.. (2006). Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochemical Pharmacology. 72(8). 941–948. 40 indexed citations

Raymond, Éric, Svein Dueland, Michael Lind, et al.. (2005). Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules. Cancer Research. 65. 936–936. 2 indexed citations

10.

Cunningham, Matthew, Sharadah Essapen, Hilary Thomas, et al.. (2005). Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. International Journal of Oncology. 27(2). 317–25. 56 indexed citations

11.

Essapen, Sharadah, Hilary Thomas, Margaret Green, et al.. (2004). The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. International Journal of Oncology. 24(2). 241–8. 34 indexed citations

12.

Madhusudan, Srinivasan, Elizabeth Flanagan, Martin Gore, et al.. (2004). A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/ neu Oncogene. Clinical Cancer Research. 10(9). 2986–2996. 55 indexed citations

13.

Modjtahedi, Helmout, David K. Moscatello, Gary Box, et al.. (2003). Targeting of cells expressing wild‐type EGFR and type‐III mutant EGFR (EGFRvIII) by anti‐EGFR MAb ICR62: A two‐pronged attack for tumour therapy. International Journal of Cancer. 105(2). 273–280. 53 indexed citations

14.

Thomas, Hilary & Helen M. Coley. (2003). Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein. Cancer Control. 10(2). 159–165. 769 indexed citations breakdown →

15.

Labeed, Fatima H., Helen M. Coley, Hilary Thomas, & Michael Hughes. (2003). Assessment of Multidrug Resistance Reversal Using Dielectrophoresis and Flow Cytometry. Biophysical Journal. 85(3). 2028–2034. 90 indexed citations

16.

Jones, Kevin, et al.. (2002). Endometrial Adenocarcinoma Following the Insertion of a Mirena IUCD. Gynecologic Oncology. 87(2). 216–218. 27 indexed citations

17.

Thomas, Hilary. (1999). Clinical governance and revalidation. Hospital Medicine. 60(12). 892–896. 6 indexed citations

18.

Dias, Sérgio, Hilary Thomas, & Frances R. Balkwill. (1998). Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. International Journal of Cancer. 75(1). 151–157. 41 indexed citations

19.

Kayal, Philip M., Sue Scott, G. V. Williams, Stephen Platt, & Hilary Thomas. (1994). Private Risks and Public Dangers.. Contemporary Sociology A Journal of Reviews. 23(1). 144–144. 17 indexed citations

20.

Thomas, Hilary, et al.. (1992). Preparing for the National Curriculum: patterns of provision in the South West. Language Learning Journal. 6(1). 36–40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact